Live Chat
Involvation is a consultancy and implementation firm that is focused on improving the supply chain and its management. In doing so, we are driven by possibilities. Our case studies show how we have helped organisations, both large and small, to take the decisive step: the step from the challenge to the result, inspired by the surprising possibilities we identified. Because that is what characterises us: we firmly believe that your supply chain offers potential for improvement. Especially if you are willing to join us in pinpointing the essence of the situation – without becoming distracted by details, symptoms and day-to-day operations.
VISIT THE WEBSITE: https://www.involvation.com/
Solentim is the trusted global leader for solutions to create, isolate, and characterize the highest value cells for the development of new biological medicines, including cell and gene therapies, monoclonal antibodies, vaccines and stem cells. For our customers, which include most of the world’s leading pharmaceutical and biotherapeutics companies, we are the partner of choice for facilitating the highest level of assurance in cell line development for therapeutic protein and viral vector production.
Our customers develop cell and antibody based therapies for a wide range of conditions including lymphomas, cancers, Crohn’s disease, rheumatoid arthritis, high cholesterol and asthma.
Our portfolio of proven and innovative instruments (including VIPS™, Cell Metric®, Cell Metric® CLD, ICON™ and STUDIUS™) are designed for single cell cloning and assurance of monoclonality. Combined with enabling reagents and our unparalleled domain expertise, we transform the speed and efficiency of clonally-derived Master Cell Bank development. Our customers trust in our technology to ensure they are confidently prepared for regulatory review.
Solentim continues to define modern assurance driven workflows for cell based and antibody based biotherapeutics including stem cells, gene therapy and immunotherapy.
VISIT THE WEBSITE: https://www.solentim.com/